Shares of Alto Neuroscience, Inc. (NYSE:ANRO – Get Free Report) have been assigned a consensus rating of “Buy” from the seven research firms that are currently covering the stock, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy rating. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $33.80.
ANRO has been the subject of several recent analyst reports. Wedbush reissued an “outperform” rating and set a $29.00 price objective on shares of Alto Neuroscience in a report on Tuesday, September 10th. William Blair reiterated an “outperform” rating on shares of Alto Neuroscience in a research note on Tuesday, September 10th. Finally, Rodman & Renshaw assumed coverage on Alto Neuroscience in a report on Friday, June 21st. They issued a “buy” rating and a $43.00 price objective for the company.
Read Our Latest Report on ANRO
Alto Neuroscience Stock Performance
Alto Neuroscience (NYSE:ANRO – Get Free Report) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.60) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.07. Sell-side analysts predict that Alto Neuroscience will post -2.63 EPS for the current fiscal year.
Insider Transactions at Alto Neuroscience
In related news, insider Adam Savitz bought 12,069 shares of the stock in a transaction dated Tuesday, July 9th. The stock was bought at an average cost of $12.60 per share, with a total value of $152,069.40. Following the completion of the acquisition, the insider now owns 36,920 shares of the company’s stock, valued at $465,192. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Institutional Investors Weigh In On Alto Neuroscience
Hedge funds have recently added to or reduced their stakes in the stock. Rhumbline Advisers bought a new position in shares of Alto Neuroscience during the second quarter worth about $113,000. Federated Hermes Inc. boosted its stake in Alto Neuroscience by 33.3% during the 2nd quarter. Federated Hermes Inc. now owns 12,000 shares of the company’s stock valued at $128,000 after purchasing an additional 3,000 shares during the period. University of Texas Texas AM Investment Managment Co. bought a new position in Alto Neuroscience in the 1st quarter worth about $340,000. Bank of New York Mellon Corp acquired a new stake in shares of Alto Neuroscience in the second quarter valued at approximately $252,000. Finally, Bowie Capital Management LLC acquired a new stake in shares of Alto Neuroscience in the second quarter valued at approximately $462,000.
Alto Neuroscience Company Profile
Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.
Recommended Stories
- Five stocks we like better than Alto Neuroscience
- Breakout Stocks: What They Are and How to Identify Them
- CarMax’s Impressive Rally: What Investors Should Watch Next
- How to Calculate Retirement Income: MarketBeat’s Calculator
- MarketBeat Week in Review – 9/23 – 9/27
- What Do S&P 500 Stocks Tell Investors About the Market?
- Wake Up to This Biotech Stock That Still Has Big Potential Upside
Receive News & Ratings for Alto Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alto Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.